Serbia Pharmaceuticals and Healthcare Report Q2 2010

Executive Summary ....................................................5
SWOT Analysis............................................................6
Serbia Pharmaceuticals And Healthcare Industry SWOT................................................. 6
Serbia Political SWOT.................. 7
Serbia Economic SWOT................ 7
Serbia Business Environment SWOT ................................................................................ 8
Pharmaceutical Business Environment Ratings ..........................................................................................9
Table: Emerging Europe – Regional Pharmaceutical Business Environment Ratings for Q210 ........................................................................... 9
Limits Of Potential Returns............................................................................................. 10
Risks To Realisation Of Returns ..................................................................................... 10
Serbia – Market Summary .........................................12
Regulatory Regime....................................................13
Intellectual Property Environment.................................................................................. 14
Pricing Regime ........................... 15
Price Cuts ................................... 16
Price Rises .................................. 16
Reimbursement Regime............... 17
Table: Serbia – Examples of Reimbursed Medicines by Category................................... 18
Industry Trends and Developments .........................19
Epidemiology.............................. 19
Communicable Diseases ................................................................................................. 19
Non-Communicable Diseases ......................................................................................... 20
Table: Disease Burden In CEE....................................................................................... 22
Healthcare Sector ....................... 23
Table: Serbia – Major General And Specialised Hospitals............................................. 23
Recent Healthcare Sector Developments ........................................................................ 25
Healthcare Insurance ................. 25
Healthcare Reform...................... 26
Medical Tourism......................... 27
Table: Serbia – Cosmetic Surgery Costs......................................................................... 27
Pharmaceutical Wholesale And Retail............................................................................ 27
Clinical Trials............................. 28
Table: Number Of Ongoing Clinical Trials In Serbia..................................................... 28
Medical Devices.......................... 29
Table: Medical Device Classification In Serbia.............................................................. 30
Industry Forecast Scenario......................................31
Overall Market Forecast................................................................................................. 31
Key Growth Factors – Industry............................................................................................ 32
Key Growth Factors – Macroeconomic .......................................................................... 33
Table: Serbia – Economic Activity.................................................................................. 34
Prescription Market Forecast......................................................................................... 35
Table: Serbia – Defined Daily Dose (DDD) Per 1,000 Inhabitants................................ 36
Patented Market Forecast............................................................................................... 37
Generics Market Forecast .............................................................................................. 38
OTC Market Forecast................. 39
Table: Serbia – Sales Of Herbal Remedies 2007 ............................................................ 40
Medical Device Market Forecasts .................................................................................. 41
Pharmaceutical Trade Forecasts .................................................................................... 42
Other Healthcare Data Forecasts................................................................................... 44
Key Risks to Forecast Scenario............................................................................ 45
Competitive Landscape............................................46
Investment Climate ..................... 46
Pharmaceutical Industry................................................................................................. 46
Table: Companies Involved In The Serbian Pharmaceutical Industry ............................. 47
Domestic Pharmaceutical Industry................................................................................. 47
Domestic Company Activity............................................................................................ 48
Foreign Pharmaceutical Industry ................................................................................... 48
Table: Proposed Members Of Serbia’s Pharmaceutical Industry Association................. 49
Foreign Company Activity .............................................................................................. 50
Company Monitor......................................................51
Multinational Company Profiles.......................................................................................... 63
Pfizer .......................................... 63
GlaxoSmithKline......................... 64
Novartis ...................................... 65
Sanofi-Aventis............................. 66
Merck & Co ................................ 67
Krka............................................ 68
Indigenous Company Profiles .............................................................................................. 51
Hemofarm (Stada) ...................... 51
Galenika ..................................... 55
Zdravlje Actavis .......................... 58
Jugoremedija .............................. 61
Country Snapshot: Serbia Demographic Data........70
Section 1: Population.................. 70
Table: Demographic Indicators, 2005-2030................................................................... 70
Table: Rural/Urban Breakdown, 2005-2030 .................................................................. 71
Section 2: Education And Healthcare............................................................................. 71
Table: Education, 2000/01.............................................................................................. 71
Table: Vital Statistics, 2005-2030................................................................................... 71
Section 3: Labour Market And Spending Power ............................................................. 72
Table: Employment Indicators, 2001-2006..................................................................... 72
Table: Average Annual Manufacturing Wages, 2000-2012 ............................................ 72
Methodology ......................................................73
How We Generate Our Pharmaceutical Industry Forecasts ................................................ 73
Pharmaceutical Business Environment Ratings Methodology ............................................. 74
Ratings Overview........................ 74
Table: Pharmaceutical Business Environment Indicators .............................................. 75
Weighting.................................... 76
Table: Weighting Of Components ................................................................................... 76
Sources ............................................ 76
Forecast Tables .........................................................77